Apogee Therapeutics, Inc. (APGE)
| Market Cap | 6.32B +242.3% |
| Revenue (ttm) | n/a |
| Net Income | -255.84M |
| EPS | -4.22 |
| Shares Out | 73.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 537,660 |
| Open | 88.62 |
| Previous Close | 88.29 |
| Day's Range | 84.88 - 88.64 |
| 52-Week Range | 34.34 - 95.32 |
| Beta | 1.02 |
| Analysts | Strong Buy |
| Price Target | 109.67 (+28.1%) |
| Earnings Date | May 11, 2026 |
About APGE
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinic... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for APGE stock is "Strong Buy." The 12-month stock price target is $109.67, which is an increase of 28.10% from the latest price.
News
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million
SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential fo...
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential fo...
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
SAN FRANCISCO and BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential fo...
Apogee Therapeutics Stock Rallies On Encouraging Eczema Drug Data Readout
The data revealed that zumilokibart demonstrated durable maintenance of response with both 3- and 6-month dosing regimens, with 75% and 85% of patients maintaining EASI-75, respectively.
Apogee Therapeutics Transcript: Study result
The phase II APEX Part A study showed zumilokibart maintained and deepened efficacy in atopic dermatitis over 52 weeks with both three- and six-month dosing, offering strong lesion and itch control an...
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis
APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including: - 75% and 85% patients maintained EASI-75 - 86% and 78% patients ma...
Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026
SAN FRANCISCO and BOSTON, March 22, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for be...
Apogee Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Upcoming maintenance data aims to validate quarterly and semi-annual dosing for atopic dermatitis, with phase 3 trials launching this year and full funding secured through 2028. Market research suppor...
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results
Zumilokibart (APG777) trials continue to advance in atopic dermatitis (AD) with plans for expansion indications underway: - APEX Phase 2 Part A 52-week data expected this month - APEX Phase 2 Part B 1...
Apogee Therapeutics to Participate in Upcoming March Conferences
SAN FRANCISCO and BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the TD Cowen 46t...
Apogee Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Recent data show rapid itch relief and durable efficacy in atopic dermatitis and asthma, with a focus on extending dosing intervals and maintaining a strong safety profile. Plans include a 2029 launch...
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026
SAN FRANCISCO and BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim E...
Apogee Therapeutics Transcript: Study Result
Interim phase I-B data for zumilokibart in asthma showed robust, durable FeNO suppression and a favorable safety profile, supporting dosing every three or six months. The results align with standard-o...
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook
Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression of...
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026
SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for bes...
Apogee Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025
Multiple pivotal clinical readouts for 777 in AD and asthma are expected in 2026, with a focus on infrequent dosing, rapid itch relief, and strong efficacy. Market research and commercial trends suppo...
Apogee Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Major clinical milestones are expected next year, including four readouts for atopic dermatitis and asthma, with a focus on combination therapies targeting IL-13 and OX40L. The strategy emphasizes bot...
Apogee Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit
Upcoming data for APG777 in asthma and atopic dermatitis could set new efficacy and durability standards, with phase 3 trials and a 2029 launch targeted. Market research shows strong physician prefere...
Apogee Therapeutics Transcript: Stifel 2025 Healthcare Conference
Multiple late-stage clinical readouts are expected in the next year, including maintenance dosing and head-to-head data versus Dupixent. The pipeline is positioned for frontline and second-line atopic...
Apogee Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
The team highlighted strong phase II data for their lead IL-13 antibody in atopic dermatitis, robust market growth, and a strategy focused on long-acting, co-formulated combinations. Key catalysts are...
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anti...
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody
Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potentia...
Apogee Therapeutics to Participate in Upcoming Conferences
SAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences...
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million
SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for bes...
Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.1% on Thursday.